視神経炎治療市場

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, clinical publications, and authoritative health organizations. Key sources included:

Regulatory & Government Authorities:

US Food & Drug Administration (FDA) – Drug approvals, clinical trial data, and safety monitoring for optic neuritis therapeutics

European Medicines Agency (EMA) – Centralized marketing authorizations and orphan drug designations for neuroinflammatory treatments

Pharmaceuticals and Medical Devices Agency (PMDA) – Japan regulatory approvals for MS-related optic neuritis therapies

Health Canada – Neurological drug approvals and special access programs

Therapeutic Goods Administration (TGA) – Australian regulatory framework for neuro-ophthalmology treatments

Medical & Scientific Organizations:

National Multiple Sclerosis Society (NMSS) – Clinical guidelines and epidemiological data on optic neuritis as initial MS presentation

American Academy of Ophthalmology (AAO) – Preferred Practice Pattern guidelines for neuro-ophthalmic disorders

North American Neuro-Ophthalmology Society (NANOS) – Clinical research and treatment protocols

International Multiple Sclerosis Genetics Consortium (IMSGC) – Genetic epidemiology and disease burden studies

European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) – Annual congress proceedings and treatment guidelines

American Academy of Neurology (AAN) – Evidence-based clinical practice guidelines

Academic & Research Databases:

National Institutes of Health (NIH) – Clinical trial registries and funding patterns for demyelinating diseases

National Center for Biotechnology Information (NCBI/PubMed) – Peer-reviewed literature on corticosteroid therapy, plasma exchange, and monoclonal antibodies

National Eye Institute (NEI) – Vision research initiatives and epidemiological studies

Cochrane Library – Systematic reviews on optic neuritis treatment efficacy

ClinicalTrials.gov – Active and completed trials for emerging therapeutics (e.g., ublituximab, ofatumumab)

Public Health & Epidemiological Sources:

Centers for Disease Control and Prevention (CDC) – National Health and Nutrition Examination Survey (NHANES) data on vision impairment

World Health Organization (WHO) – Global Burden of Disease Study estimates for MS and associated optic neuropathies

Multiple Sclerosis International Federation (MSIF) – Atlas of MS prevalence and incidence statistics

National Center for Health Statistics (NCHS) – Hospital discharge data and outpatient department visits

Eurostat Health Database – European healthcare utilization and pharmaceutical expenditure

Market & Industry Intelligence:

IQVIA Institute for Human Data Science – Real-world evidence and prescription analytics

Evaluate Pharma – Pipeline analysis and commercial forecasting for neurology therapeutics

GlobalData Healthcare – MS market landscape and competitive intelligence

These sources were utilized to collect epidemiological statistics on MS-associated optic neuritis, regulatory approval timelines for disease-modifying therapies (DMTs), clinical safety profiles of high-dose corticosteroids versus plasma exchange, patient demographic trends across age cohorts, and market landscape analysis for corticosteroids, immunomodulators, monoclonal antibodies, and neuroprotective agents.

In order to gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. Chief executive officers, vice presidents of clinical development, directors of regulatory affairs, and heads of commercial strategy from pharmaceutical companies creating treatments for MS and optic neuritis as well as medical device companies that specialize in optical coherence tomography (OCT) diagnostic equipment were examples of supply-side sources. Neuro-ophthalmologists, MS specialists (neurologists), clinical pharmacists from university medical institutions, procurement leaders from hospital pharmacy departments, and payers from managed care organizations were examples of demand-side sources. Primary research obtained information on clinical adoption patterns of oral versus intravenous corticosteroid protocols, pricing strategies for branded versus generic methylprednisolone, and reimbursement dynamics for plasma exchange procedures. It also verified product pipeline timelines for novel neuroprotective agents and validated market segmentation across treatment modalities (medications, physical therapy, and surgical interventions).

Primary Respondent Breakdown:

By Designation: C-level Executives (28%), Director Level (32%), Others (40%)

By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)

Global market valuation was derived through revenue mapping and procedure volume analysis. The methodology included:

Identification of 35+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America specializing in corticosteroids, immunomodulators, and plasma exchange equipment

Product mapping across oral corticosteroids, intravenous methylprednisolone, monoclonal antibodies (e.g., natalizumab, alemtuzumab), and physical rehabilitation devices

Analysis of reported and modeled annual revenues specific to optic neuritis and broader MS treatment portfolios

Coverage of manufacturers representing 72-78% of global market share in 2024

Extrapolation using bottom-up (treated patient population × therapy cost by country) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations for medications, physical therapy services, and surgical interventions